Evidence map›Paper›PMID 16432160›Full record

ArticleMolecular cancer therapeutics2006

Inhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisons.

Hiroshi Y Yamada, Gary J Gorbsky

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hiroshi Y YamadaMolecular, Cell, and Developmental Biology Research Program, Oklahoma Medical Research Foundation, 825 Northeast 13th Street, MS48, Oklahoma City, 73104-5097, USA. Hiroshi-yamada@omrf.ouhsc.edu
Gary J Gorbsky
Oklahoma Medical Research Foundation · US

Funding

CHROMOSOME MOVEMENT IN PROMETAPHASER01GM050412 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GORBSKY, GARY J. · 1994 to 2012
$4.5M
NIGMS NIH HHS R01 GM050412NIGMS NIH HHS R01-GM50412
6 · The paper itself

Abstract

Mitotic spindle poisons (e.g., Taxol and vinblastine), used as chemotherapy drugs, inhibit mitotic spindle function, activate the mitotic spindle checkpoint, arrest cells in mitosis, and then cause cell death by mechanisms that are poorly understood. By expression cloning, we identified a truncated version of human TRIP1 (also known as S8, hSug1), an AAA (ATPases associated with diverse cellular activities) family ATPase subunit of the 19S proteasome regulatory complex, as an enhancer of spindle poison-mediated apoptosis. Stable expression of the truncated TRIP1/S8/hSug1 in HeLa cells [OP-TRIP1(88-406)] resulted in a decrease of measurable cellular proteasome activity, indicating that OP-TRIP1(88-406) had a dominant-negative effect on proteasome function. OP-TRIP1(88-406) revealed an increased apoptotic response after treatment with spindle poisons or with proteasome inhibitors. The increased apoptosis coincided with a significant decrease in expression of BubR1, a kinase required for activation and maintenance of the mitotic spindle checkpoint in response to treatment with spindle poisons. Small interfering RNA (siRNA)-mediated knockdown of TRIP1/S8/hSug1 resulted in a reduction of general proteasome activity and an increase in mitotic index. The siRNA treatment also caused increased cell death after spindle poison treatment. These results indicate that inhibition of TRIP1/S8/hSug1 function by expression of a truncated version of the protein or by siRNA-mediated suppression enhances cell death in response to spindle poison treatment. Current proteasome inhibitor drugs in trial as anticancer agents target elements of the 20S catalytic subcomplex. Our results suggest that targeting the ATPase subunits in 19S regulatory complex in the proteasome may enhance the antitumor effects of spindle poisons.

Indexed as

MitosisAdaptor Proteins, Signal TransducingAnimalsApoptosisATPases Associated with Diverse Cellular ActivitiesCysteine Proteinase InhibitorsHeLa CellsHumansLeupeptinsLIM Domain ProteinsNocodazolePaclitaxelPeptide FragmentsProteasome Endopeptidase ComplexProteasome InhibitorsProtein KinasesAdaptor Proteins, Signal TransducingATPases Associated with Diverse Cellular Activitiesbenzyloxycarbonylleucyl-leucyl-leucine aldehydeBUB1 protein, humanBub1 spindle checkpoint proteinCysteine Proteinase InhibitorsLeupeptinsLIM Domain ProteinsNocodazolePaclitaxelPeptide FragmentsProteasome Endopeptidase ComplexProteasome InhibitorsProtein KinasesProtein Serine-Threonine KinasesPSMC5 protein, humanRNA, Small InterferingTranscription Factors

Identifiers

PMID16432160
PMCPMC1630635
OpenAlexW2163086956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.